HDAC inhibitors, as a new class of anti-tumor agents, such as trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), valproic acid, depsipeptide and sodium butyrate, are useful for the downregulation and inhibition of cancer growth [31,32]. The gene discussed is HDAC9; the disease is cancer.